| Literature DB >> 29264452 |
Julius O Nyalwidhe1,2, Glen R Gallagher3, Lindsey M Glenn4, Margaret A Morris4, Pranitha Vangala5, Agata Jurczyk6, Rita Bortell6, David M Harlan3, Jennifer P Wang3, Jerry L Nadler4.
Abstract
Enteroviral infections have been associated with the development of type 1 diabetes (T1D), a chronic inflammatory disease characterized by autoimmune destruction of insulin-producing pancreatic beta cells. Cultured human islets, including the insulin-producing beta cells, can be infected with coxsackievirus B4 (CVB4) and thus are useful for understanding cellular responses to infection. We performed quantitative mass spectrometry analysis on cultured primary human islets infected with CVB4 to identify molecules and pathways altered upon infection. Corresponding uninfected controls were included in the study for comparative protein expression analyses. Proteins were significantly and differentially regulated in human islets challenged with virus compared with their uninfected counterparts. Complementary analyses of gene transcripts in CVB4-infected primary islets over a time course validated the induction of RNA transcripts for many of the proteins that were increased in the proteomics studies. Notably, infection with CVB4 results in a considerable decrease in insulin. Genes/proteins modulated during CVB4 infection also include those involved in activation of immune responses, including type I interferon pathways linked to T1D pathogenesis and with antiviral, cell repair, and inflammatory properties. Our study applies proteomics analyses to cultured human islets challenged with virus and identifies target proteins that could be useful in T1D interventions.Entities:
Keywords: coxsackievirus; immune response; inflammation; innate immunity; insulin; mass spectrometry; pancreatic islets; proteomics; type 1 diabetes
Year: 2017 PMID: 29264452 PMCID: PMC5686651 DOI: 10.1210/js.2017-00278
Source DB: PubMed Journal: J Endocr Soc ISSN: 2472-1972
Differential Protein Expression Between CVB4- vs Mock-Infected Primary Human Islets at 48 hpi
| Protein/Gene | Fold Difference | Protein/Gene | Fold Difference |
|---|---|---|---|
| CXB4 | ↑8.089 | PC | ↑1.284 |
| MX1 | ↑7.199 | SLC25A4 | ↑1.284 |
| ISG15 | ↑5.817 | SLC25A5 | ↑1.207 |
| IFIT3 | ↑5.138 | IDH3B | ↑1.185 |
| CXCL1 | ↑4.112 | MCCC1 | ↑1.108 |
| CXCL8 | ↑4.014 | HIBCH | ↑1.078 |
| IFIT1 | ↑3.571 | SAMHD1 | ↑1.066 |
| HIC1 | ↑3.484 | PPOX | ↑1.062 |
| TAP1 | ↑3.051 | EIF2AK2 | ↑1.041 |
| ICAM1 | ↑2.833 | RBM14 | ↓−1.020 |
| IFIT2 | ↑2.769 | UCHL1 | ↓−1.027 |
| HLA-B | ↑2.7624 | SEC24C | ↓−1.132 |
| OAS3 | ↑2.390 | RAP1GAP2 | ↓−1.249 |
| TAPBP | ↑2.286 | PDCD5 | ↓−1.275 |
| STAT1 | ↑2.183 | GPD1 | ↓−1.277 |
| MRPS36 | ↑2.146 | NACA | ↓−1.312 |
| HLA-C | ↑1.840 | PCP4 | ↓−1.338 |
| DDX58 | ↑1.830 | GHRL | ↓−1.404 |
| TYMP | ↑1.793 | PLCXD3 | ↓−1.421 |
| PML | ↑1.651 | VAT1L | ↓−1.463 |
| LGALS9 | ↑1.625 | RPL27 | ↓−1.503 |
| GBP1 | ↑1.563 | PRSS2 | ↓−1.689 |
| HLA-A | ↑1.477 | PPP1R1A | ↓−1.752 |
| EHD4 | ↑1.417 | UBQLN2 | ↓−1.891 |
| WARS | ↑1.379 | ATP6AP1 | ↓−1.970 |
| APOL2 | ↑1.378 | INS | ↓−2.152 |
| LAP3 | ↑1.337 | WIBG | ↓−2.315 |
| COX7C | ↑1.312 | REG3A | ↓−3.103 |
Summary of IPA of CVB4-Infected Islets vs Mock-Infected Islets
| Top canonical pathways | ||
| Name | Overlap | |
| Interferon signaling | 7.45E-10 | 16.7% (6/36) |
| Antigen presentation pathways | 7.35E-08 | 13.2% (5/38) |
| T1D signaling | 1.28E-05 | 4.7% (5/106) |
| Activation of IRF by cytosolic PRRs | 2.57E-05 | 6.7% (4/60) |
| Th1 pathway | 3.44E-05 | 3.8% (5/130) |
| Top upstream regulators | ||
| Upstream regulator | Predicted activation | |
| IFNG | 1.12E-22 | Activated |
| IFNL1 | 6.98E-22 | Activated |
| MAPK1 | 9.78E-19 | Inhibited |
| IFNA2 | 4.17E-16 | Activated |
| IFNB1 | 3.95E-14 | Activated |
| Top diseases and bio functions | ||
| Diseases and disorders | ||
| Name | Number of molecules | |
| Antimicrobial response | 2.85E-03–4.91E-12 | 11 |
| Inflammatory disease | 2.19E-02–4.91E-12 | 28 |
| Dermatological diseases and conditions | 1.14E-02–2.04E-09 | 21 |
| Organismal injury and abnormalities | 2.19E-02–2.04E-09 | 53 |
| Immunological disease | 2.18E-02–1.79E-08 | 32 |
| Molecular and cellular functions | ||
| Name | Number of molecules | |
| Cell signaling | 1.08E-02–2.20E-07 | 14 |
| Cell death and survival | 2.13E-02–3.53E-07 | 23 |
| Cellular growth and proliferation | 1.98E-02–1.05E-06 | 26 |
| Cellular movement | 2.25E-02–2.94E-05 | 17 |
| Carbohydrate metabolism | 1.70E-02–3.26E-05 | 4 |
| Physiological system development and function | ||
| Name | Number of molecules | |
| Cardiovascular system development and function | 1.85E-02–2.17E-05 | 10 |
| Organismal development | 1.85E-02–2.17E-05 | 12 |
| Tissue development | 1.85E-02–6.40E-05 | 10 |
| Tissue morphology | 1.98E-02–6.92E-03 | 7 |
| Hematological system development and function | 1.98E-02–1.21E-04 | 11 |
| Top regulator effect networks | ||
| ID regulators | Diseases and functions | Consistency score |
| BTK, EIF2AK2, IFNA2, IFNG, IFNL1, PRL, SOCS1, TLR7, TLR9 | Relapsing-remitting multiple sclerosis and replication of virus replicon | 33.5 |
| JAK1, NLRC5, TGM2 | Viral infection | 2.774 |
| MAPK1 | Viral infection | −1.664 |
| IFNA2 | Cell death | −2.333 |
| IL1RN | Cell death | −2.828 |
| Top networks | ||
| ID-associated network functions | Score | |
| Antimicrobial response, inflammatory response, infectious diseases | 40 | |
| Cellular growth and proliferation, development, cellular development, and lymphoid tissue structure | 14 | |
| Cell signaling, cancer, organismal injury, and abnormalities | 8 | |
| Developmental disorder, hereditary disorder, metabolic disease | 2 | |
| Cellular assembly and organization, gastrointestinal disease, and hepatic system disease | 2 | |
Abbreviations: IRF, IFN-regulatory factor; PRR, pattern recognition receptor; Th1, T helper 1.
Figure 1.IPA Top Regulator Effect with the highest consistent score of 33.5 (Table 2) showing inhibited and activated diseases and functions and the associated molecules. Proteins shown in orange are activated, whereas those in blue are inhibited in the CVB4-infected islets. Orange dashed lines depict activation, whereas blue dashed lines depict inhibition. The predictions indicate that pathways associated with the “replication of viral replicon” are inhibited upon CVB4 infection, whereas pathways associated with “relapsing and remitting multiple sclerosis” (associated with the inflammatory immune response) are activated. Yellow dashed lines depict findings inconsistent with the state of downstream molecules. Gray lines show effects not predicted.
Figure 2.IPA Top Network generated from differentially regulated proteins between CVB4- and mock-infected primary human islets. Proteins shown in color are significantly differentially expressed based on the statistical analysis (red, upregulated; green, downregulated). A solid line represents a direct interaction between the two gene products, and a dotted line represents an indirect interaction. STAT1 is significantly upregulated and is one of the central nodes in the network.
Figure 3.Gene expression in cultured primary human islets following challenge with CVB4 or poly I:C. The heat map depicts the five clusters of genes that have at least twofold change compared with mock in the average of the four replicates. The color bar highlights five clusters obtained after k-means clustering. Genes in boldface are also found in Table 1. Averages for four independent human donors were used. Time points are indicated. Average CVB copies per condition, measured by NanoString, are shown in the bottom panel; error bars represent the standard deviation.
Figure 4.Gene expression in EndoC-βH1 cells following challenge with CVB4 (MOI of 10) compared with mock. The heat map shows five clusters obtained after k-means clustering of genes having at least a twofold change with CVB4 compared with mock. Clusters 1, 3, 4, and 5 have genes induced with CVB4. Cluster 2 (light blue) has genes downregulated with CVB4, including INS. Averages for three independent experiments were used. Time points are indicated. Average CVB copies per condition, measured by NanoString, are shown in the bottom panel; error bars represent the standard deviation.